# Nine Square Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nine-square-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.ninesquaretx.com
- Total disclosed funding: $4.2M
- Latest round: Series A (Feb 3, 2021)
- Investors on record: 1

## About

Based in the US, Nine Square Therapeutics, Inc. focuses on innovative therapeutics for neurodegenerative diseases through advanced drug discovery platforms.Nine Square Therapeutics, Inc. specializes in developing treatments for neurodegenerative diseases. Founded in 2020 by Matt Jacobson and Steve Altschuler, the company is headquartered in South San Francisco, US. The company has completed three deals, with its most recent funding round occurring on September 12, 2023. This round included a USD 4.5 mn Grant from the Michael J. Fox Foundation, bringing the total amount raised to USD 3.20 mn. Robert Paul serves as the CEO.Nine Square Therapeutics primarily focuses on accelerating the development of innovative therapeutics targeting neurodegenerative diseases. Their core offerings revolve around pioneering drug discovery platforms that aim to identify and develop treatments for previously considered undruggable targets. By leveraging advanced scientific methodologies, the company seeks to create solutions that can significantly alter the course of conditions such as Alzheimer's and Parkinson's diseases. The end users of their products include pharmaceutical companies, research institutions, and ultimately, patients suffering from these debilitating ailments. Nine Square Therapeutics serves a global market, with particular emphasis on North America and Europe, where the need for effective treatments in the neurodegenerative space is critical.Revenue generation for Nine Square Therapeutics is primarily structured through partnerships and collaborations with pharmaceutical companies and research organizations. These strategic alliances often involve joint ventures on drug development initiatives, where each party shares the financial responsibilities and potential returns associated with bringing new therapies to market. Flagship products derived from their research pipeline are offered under specific licensing agreements, allowing clients to access and implement these innovations in their own therapeutic portfolios. The transaction structure typically encompasses upfront payments, milestone payments based on developmental success, and royalties from the sales of products once they reach commercialization. The company's revenue model is intricately linked to the progression of its research initiatives and the resulting market adoption of its therapeutic innovations.In September 2023, Nine Square Therapeutics, Inc. received USD 4.5 mn in grant funding from the Michael J. Fox Foundation. The company will utilize this funding to support the increasing development of its novel therapeutic treatment for Parkinson's disease. Future growth plans include the design and launch of new products aimed at addressing critical needs in neurodegenerative diseases, with continued focus on expanding their reach in North America and Europe.

## Funding rounds

- Series A, Feb 3, 2021, $3.2M — Apple Tree Partners
- Series A, Jun 16, 2020, $1M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A